Propanc Biopharma, Inc. Common Stock Working Capital to Net Assets Ratio
Propanc Biopharma, Inc. Common Stock working capital to net assets ratio. Propanc Biopharma, Inc. Common Stock (PPCB) has a Working Capital to Net Assets ratio of 55.2% as of June 2026. Working capital of $5.19 Million (current assets of $8.54 Million minus current liabilities of $3.35 Million) is measured against net assets of $9.40 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Propanc Biopharma, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Propanc Biopharma, Inc. Common Stock (2010–2026)
Working capital to net assets ratio of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. This chart shows how Propanc Biopharma, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2010 to 2026. As of June 2026, the ratio stands at 55.2%, reflecting working capital of $5.19 Million against net assets of $9.40 Million USD. See Propanc Biopharma, Inc. Common Stock defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Propanc Biopharma, Inc. Common Stock Working Capital to Net Assets Ratio by Year (2010–2026)
Propanc Biopharma, Inc. Common Stock working capital to net assets ratio by year from 2010 to 2026. The table below presents the year-by-year Working Capital to Net Assets ratio for Propanc Biopharma, Inc. Common Stock from 2010 to 2026, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Propanc Biopharma, Inc. Common Stock total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 55.2% | $5.19 Million | $9.40 Million | $8.54 Million | $3.35 Million | ▲ +35.2 pp |
| 2025 | 20.0% | $2.77 Million | $13.91 Million | $8.35 Million | $5.58 Million | ▼ -79.7 pp |
| 2024 | 99.7% | $-3.77 Million | $-3.78 Million | $25.44K | $3.79 Million | ▼ -1.0 pp |
| 2023 | 100.7% | $-3.14 Million | $-3.12 Million | $19.04K | $3.16 Million | ▼ -0.1 pp |
| 2022 | 100.8% | $-3.05 Million | $-3.02 Million | $15.03K | $3.06 Million | ▲ +0.6 pp |
| 2021 | 100.2% | $-3.07 Million | $-3.07 Million | $6.60K | $3.08 Million | ▼ -0.6 pp |
| 2020 | 100.8% | $-3.67 Million | $-3.64 Million | $69.02K | $3.74 Million | ▲ +0.6 pp |
| 2019 | 100.2% | $-4.31 Million | $-4.30 Million | $91.13K | $4.40 Million | ▲ +0.1 pp |
| 2018 | 100.2% | $-6.76 Million | $-6.75 Million | $60.89K | $6.82 Million | ▼ -0.1 pp |
| 2017 | 100.2% | $-5.45 Million | $-5.44 Million | $81.98K | $5.54 Million | ▼ -0.4 pp |
| 2016 | 100.6% | $-2.58 Million | $-2.57 Million | $362.77K | $2.94 Million | ▲ +0.5 pp |
| 2015 | 100.2% | $-3.06 Million | $-3.05 Million | $621.89K | $3.68 Million | ▲ +0.2 pp |
| 2014 | 100.0% | $-1.41 Million | $-1.41 Million | $113.75K | $1.52 Million | ▼ -0.1 pp |
| 2013 | 100.1% | $-793.01K | $-792.48K | $1.21K | $794.22K | ▼ -0.8 pp |
| 2012 | 100.9% | $-542.54K | $-537.92K | $41.65K | $584.19K | ▲ +1.2 pp |
| 2011 | 99.7% | $10.47 Million | $10.51 Million | $10.78 Million | $306.85K | ▼ -2.4 pp |
| 2010 | 102.1% | $-190.82K | $-186.90K | $39.95K | $230.76K | — |